Is Clozapine-induced Weight Gain Dose-dependent? Results From a Prospective Cohort Study.

ABSTRACT:

Background

Antipsychotic-induced metabolic adverse effects are risk factors for cardiometabolic comorbidities. Whether dose lowering could mitigate such effects remains unclear. The present study aims to investigate the associations between clozapine doses and modifications of weight, blood pressure, blood glucose, and lipid levels.

Study design

Linear mixed-effects models of weight changes over 1 year and of variations of other metabolic parameters over 4 months were applied to a prospective cohort of 115 patients. Age- and sex-stratified analyses of weight changes were also performed.

Study results

Each 100 mg dose increment of clozapine was associated on average with a +0.48% weight increase (P = .004) over 1 year of treatment. Weight increase was greater for treat

SUBMITTER: Piras M 

PROVIDER: S-EPMC10318871 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature